FDA Clears FluoGuide's IND for FG001
FluoGuide has obtained FDA clearance for its Investigational New Drug (IND) application regarding FG001 in high-grade glioma. This regulatory step transitions the asset into late-clinical development towards U.S. registration. The company also confirmed FDA alignment on the U.S. Phase II trial design and key elements of the subsequent Phase III program.
